Objective This research examined the association between the brain-derived neurotrophic factor (BDNF) (Val66Met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in treatment-refractory depression. patients’ clinical improvement was evaluated using the HAMD-17. Patients with at least a 50% decrease… Continue reading Objective This research examined the association between the brain-derived neurotrophic factor